Literature DB >> 12223010

A hybrid endovascular procedure to preserve internal iliac artery patency during endovascular repair of aortoiliac aneurysms.

Robert J Hinchliffe1, Brian R Hopkinson.   

Abstract

PURPOSE: To demonstrate the feasibility of a hybrid endovascular procedure to preserve blood flow in the internal iliac arteries (IIA) during aortoiliac endografting. TECHNIQUE: When aneurysmal dilatation makes the distal neck in the common iliac artery (CIA) too short for an adequate seal, the CIA bifurcation is exposed via an extraperitoneal approach after endograft deployment. Via an arteriotomy in the CIA, the distal end of the stent-graft is sutured to the CIA bifurcation under direct vision to preserve IIA blood flow. This approach has been successful in preserving IIA blood flow in 5 of 7 endograft procedures; in the other 2, IIA occlusion was a predictable event.
CONCLUSIONS: Direct suturing of an aortoiliac stent-graft to the CIA bifurcation via an extraperitoneal approach is a useful method of maintaining IIA perfusion. However, further study is required to identify patients at high risk of pelvic ischemia who would benefit from such intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12223010     DOI: 10.1177/152660280200900417

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  2 in total

1.  8-Year Long-Term Outcome Comparison: Two Ways to Exclude the Internal Iliac Artery during Endovascular Aorta Repair (EVAR) Surgery.

Authors:  Han Luo; Bin Huang; Ding Yuan; Yi Yang; Fei Xiong; Guojun Zeng; Zhoupeng Wu; Xiyang Chen; Xiaojiong Du; Xiaorong Wen; Chuncheng Liu; Hongliu Yang; Jichun Zhao
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

2.  Using a surgeon-modified iliac branch device to preserve the internal iliac artery during endovascular aneurysm repair: single-center experiences and early results.

Authors:  Wei-Wei Wu; Chen Lin; Bao Liu; Chang-Wei Liu
Journal:  Chin Med J (Engl)       Date:  2015-03-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.